A NEW POSSIBILITY FOR BODY REGULATION?

Researchers are excitedly examining retatrutide, a novel medication developed by Eli Lilly, as a significant advance in body reduction . Unlike many earlier approaches, retatrutide is a twin-action compound targeting both GLP-1 and GIP, chemicals that affect appetite and blood sugar regulation .